Literature DB >> 11999626

Electro-ophthalmological recovery after withdrawal from vigabatrin.

Hellen S Graniewski-Wijnands1, Kors van der Torren.   

Abstract

UNLABELLED: This study describes the effects of stopping of the anti-epileptic drug vigabatrin on the visual field and electrophysiological changes in one third of the group of patients which is described in the paper 'Visual field and electrophysiological abnormalities due to vigabatrin' (Van der Torren and Graniewski, 2002). In 1997 several reports described the possible oculotoxic effect of vigabatrin followed by a reconsideration of this medication in epileptic patients. Vigabatrin was discontinued in one-third of the patients on chronic medication (mean duration 4.8 years). The visual field and electrophysiological examinations were repeated every 3 months if possible, otherwise at 6-month intervals. The EOG Arden index and the ERG rod b-wave showed a significant improvement when vigabatrin was discontinued. Repeated examinations of visual fields and electrophysiology shortly after discontinuation of the drug (between 1 and 3 months) and later on after 6 months and 1 year showed a recovery of the EOG Arden index and the ERG rod b-wave during this period. The visual fields did not change in either direction.
CONCLUSION: the recovery effect is a strong argument for the hypothesis that the reduction in EOG and ERG b-wave is an oculotoxic effect. The electrophysiological improvement during 6 months or longer after discontinuation and the unchanged visual fields are an argument for the hypothesis that the visual field represents the irreversible intoxicating effect on the retina, whereas the electrophysiology represents a more direct effect on the retinal glial cells level.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11999626     DOI: 10.1023/a:1014607331200

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  12 in total

1.  Long term changes in the visual fields of patients with temporal lobe epilepsy using vigabatrin.

Authors:  P Hardus; W M Verduin; G Postma; J S Stilma; T T Berendschot; C W van Veelen
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

2.  Severe persistent visual field constriction associated with vigabatrin.

Authors:  T Eke; J F Talbot; M C Lawden
Journal:  BMJ       Date:  1997-01-18

3.  Immunocytochemical evidence that vigabatrin in rats causes GABA accumulation in glial cells of the retina.

Authors:  M J Neal; J R Cunningham; M A Shah; S Yazulla
Journal:  Neurosci Lett       Date:  1989-03-13       Impact factor: 3.046

4.  Outer retinal dysfunction in patients treated with vigabatrin.

Authors:  C F Arndt; P Derambure; S Defoort-Dhellemmes; J C Hache
Journal:  Neurology       Date:  1999-04-12       Impact factor: 9.910

5.  Standard for clinical electroretinography (1994 update).

Authors:  M F Marmor; E Zrenner
Journal:  Doc Ophthalmol       Date:  1995       Impact factor: 2.379

6.  Standard for clinical electro-oculography. International Society for Clinical Electrophysiology of Vision.

Authors:  M F Marmor; E Zrenner
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

7.  Visual field defects associated with vigabatrin therapy.

Authors:  M C Lawden; T Eke; C Degg; G F Harding; J M Wild
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

8.  Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings.

Authors:  G L Krauss; M A Johnson; N R Miller
Journal:  Neurology       Date:  1998-03       Impact factor: 9.910

9.  [Disorders of color perception and increase glare sensitivity in phenytoin and carbamazepine therapy. Ocular side effects of anticonvulsants].

Authors:  A Bayer; H J Thiel; E Zrenner; W Paulus; S Ried; D Schmidt
Journal:  Nervenarzt       Date:  1995-02       Impact factor: 1.214

View more
  7 in total

1.  Retinal function in rabbits does not improve 4-5 months after terminating treatment with vigabatrin.

Authors:  Ulrika Kjellström; Sten Kjellström; Anitha Bruun; Sten Andréasson; Vesna Ponjavic
Journal:  Doc Ophthalmol       Date:  2006-01       Impact factor: 2.379

2.  Electroretinographic (ERG) responses in pediatric patients using vigabatrin.

Authors:  Anne Moskowitz; Ronald M Hansen; Susan E Eklund; Anne B Fulton
Journal:  Doc Ophthalmol       Date:  2012-03-20       Impact factor: 2.379

3.  Vigabatrin Retinal Toxicity First Detected with Electroretinographic Changes: A Case Report.

Authors:  Dianne Barrett; Jin Yang; Tharikarn Sujirakul; Stephen H Tsang
Journal:  J Clin Exp Ophthalmol       Date:  2014

4.  Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study.

Authors:  John M Wild; Catherine Chiron; Hyosook Ahn; Michel Baulac; Joseph Bursztyn; Enrico Gandolfo; Ivan Goldberg; Francisco Javier Goñi; Florence Mercier; Jean-Philippe Nordmann; Avinoam B Safran; Ulrich Schiefer; Emilio Perucca
Journal:  CNS Drugs       Date:  2009-11       Impact factor: 5.749

5.  Changes in the electroretinogram resulting from discontinuation of vigabatrin in children.

Authors:  Carol A Westall; Rita Nobile; Sharon Morong; J Raymond Buncic; William J Logan; Carole M Panton
Journal:  Doc Ophthalmol       Date:  2003-11       Impact factor: 2.379

6.  Dose-related changes in retinal function and PKC-alpha expression in rabbits on vigabatrin medication. Effect of vigabatrin in the rabbit eye.

Authors:  Ulrika Kjellström; Anitha Bruun; Fredrik Ghosh; Sten Andréasson; Vesna Ponjavic
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-05-03       Impact factor: 3.117

7.  Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy.

Authors:  Ulrika Kjellström; Monica Lövestam-Adrian; Sten Andréasson; Vesna Ponjavic
Journal:  Doc Ophthalmol       Date:  2008-01-10       Impact factor: 2.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.